Clareo Health | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
Have a length of disease duration, from first symptom, of less than (\<) 10 years
Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
Suboptimal disease control while on a DMT
Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug
You may not be if
Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
Inability to complete an Magnetic Resonance Imaging (MRI) procedure
Known presence of other neurological disorders
Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
History or currently active primary or secondary immunodeficiency
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
History of opportunistic infections
History or known presence of recurrent or chronic infection
History of malignancy
Congestive heart failure
Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds
